Objective To observe the clinical effect and safety- of dinoprostone in cervical ripening and induction of full-term pregnancy.Methods In accordance with the principle of informed consent, a case-control study- was carried ont among 120 pregnant women who were divided into trial group ( 80 cases ) and control group ( 40 cases ) according to the ratio of 2:1 by drawing lot. In the trial group one piece of dinoprostone was put into posterior fornix and in the control group low dosage of oxytocin was given through IVD ( 5％ Glucose 500mL +Oxytocin 2.5IU ). The Bishop scores, uterine contraction, delivery time and pregnancy outcomes between two groups were compared.Results After drug administration the 12h Bishop score of the trial group was 8.64 _+ 2.02, which was significantly higher than that ( 5.89 ±1.98 ) in the control group ( t = 7.08, P ＜ 0.01 ). The rate of cesarean section in the trial group was lower than that in the control group (x2 = 10.55, P ＜ 0.01 ). The differences in the incidence of fetal distress(x2 = 0.01, P ＞ 0.05 )and neonatal asphyxia(x2 = 0.38, P ＞0.05 )between two groups were not significant ( P ＞ 0.05 ). Conclusion Dinoprostone can effectively enhance cervical ripening, shorten parturient time and increase vaginal delivery- rate. It can be applied in clinics safely.%目的 观察欣普贝生对足月妊娠促宫颈成熟和引产的临床效果及安全性.方法 采用病例对照研究的方法,按照知情同意的原则,将120例孕妇用抽签法以2:1分为试验组80例及对照组40例.试验组采用欣普贝生1枚放置于阴道后穹窿;对照组静脉点滴小剂量(5%葡萄糖注射液500mL+催产素2.5IU)催产素,比较两组用药后的宫颈Bishop评分和宫缩、分娩的发生时间以及妊娠结局.结果 试验组用药后12小时宫颈评分8.64±2.02分,明显高于对照组的5.89±1.98分(t=7.08,P<0.01);试验组剖宫产率低于对照组(χ2=10.55,P<0.01).两组间胎儿窘迫发生率(χ2=0.01,P>0.05)、新生儿窒息率(χ2=0.38,P>0.05)比较均无显著性差异.结论 欣普贝生能够有效地促进宫颈成熟,缩短临产时间,增加阴道分娩率,可安全地用于临床.
展开▼
